Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

A Phase I Window, Dose Escalating and Safety Trial of Metformin in Combination With Induction Chemotherapy in Relapsed Refractory Acute Lymphoblastic Leukemia: Metformin With Induction Chemotherapy of Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD)

H. Lee Moffitt Cancer Center and Research Institute will be the Sunshine Project Coordinator, but will not be recruiting locally.

The purpose of the trial is to study the clinical and biological effects of metformin in combination with standard systemic chemotherapy in a disease (relapsed ALL) that has a dismal outcome, as well as to do a dose escalation study to find the Maximum Tolerated Dose (MTD) of metformin in conjunction with ALL therapy. There have also been analysis of patients enrolled on trials who were diabetics on metformin and their outcome was better than patients on the same trial that were not on metformin as their antihyperglycemic.

Study Overview

• Status: Completed
• Conditions: Acute Lymphoblastic Leukemia
• Intervention / Treatment: Drug: Metformin; Drug: Vincristine; Drug: Dexamethasone; Drug: PEG-asparaginase; Drug: Doxorubicin; Drug: Intrathecal chemotherapy

Detailed Description

This will be a phase I protocol of Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and metformin conducted in the Sunshine Project sites for children with recurrent ALL. All sites will be eligible to open this study, provided they agree to adhere to all study procedures and make a good faith effort to obtain all pharmacodynamic and pharmacokinetic evaluations requested.

• Study Type: Interventional
• Enrollment (Actual): 14
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Florida
    • Miami, Florida, United States, 33136
      • Holtz Children's Hospital University of Miami Miller School of Medicine
    • Orlando, Florida, United States, 32806
      • Arnold Palmer Hospital for Children
    • Saint Petersburg, Florida, United States, 33701
      • All Children's Hospital
  • New York
    • The Bronx, New York, United States, 10467
      • Montefiore Medical Center, The Children's Hospital at Montefiore
  • Ohio
    • Columbus, Ohio, United States, 43205
      • Nationwide Children's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years to 26 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• ALL or lymphoblastic lymphoma patients in first or higher relapse.
• Male or Female age 1-30 years at initial diagnosis.
• Signed informed consent.
• Karnofsky / Lansky score above 50%.
• No known contraindications to intended therapies.
• Prior anthracycline exposure: Patients must have had less than 350 mg/m^2 lifetime exposure of anthracycline chemotherapy.
• It must be at least 6 months since the last treatment with a "VPLD" induction/re-induction type regimen (i.e. anthracycline, steroid, asparaginase and vincristine).

• Patients must have adequate organ function.

  • Adequate renal function defined as serum creatinine < 1.5 x upper limit of normal (ULN) for age.
  • Total bilirubin < 1.5 X ULN for age.
  • Alanine transaminase (ALT) < 5 X ULN for age, unless the elevation is disease-related.
  • Adequate cardiac function as defined as shortening fraction of > 27% by echocardiogram or ejection fraction > 45% by gated radionuclide study.

Exclusion Criteria:

• Significant renal impairment as determined per investigator discretion.
• Patients planning on receiving other investigational agents while on this study.
• Patients planning on receiving other anti-cancer therapies while on this study.
• Patients with active infection defined as: positive blood culture within 48 hours of study registration; need for supplemental oxygen or vasopressors within 48 hours of study entry.
• Patient receiving corticosteroids, aside from dexamethasone treatment directed at leukemia.
• Known intolerance to doxorubicin, metformin, or vincristine.
• Patients who have started protocol therapy prior to enrollment. Patient may still enroll if IT therapy was given within 72 hours of study enrollment as part of the diagnostic lumbar procedure.
• Patients may be on hydroxurea until the first dose of metformin is to be given.
• Patients who have a need to continue hydroxurea while on study (Patients may continue on hydroxurea only until the first dose of metformin is to given).
• Patients with creatinine more than 1.5 x the ULN

• Patients must have recovered from the acute side effects of all prior anticancer therapy.

  • At least 1 week from prior cytotoxic chemotherapy.
  • At least 4 weeks from craniospinal irradiation.
  • At least 4 months since hematopoietic stem cell transplant (HSCT) with no evidence of active graft-versus-host disease (GVHD).
• Pregnant or lactating women.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: VLPD Regimen; Induction will consist of vincristine, dexamethasone, doxorubicin and PEG asparaginase (so called VPLD - dexamethasone is substituted for prednisone and PEG asparaginase is substituted for L-asparaginase) in combination with metformin. Eligible patients will receive 24 hours of metformin followed by induction. Intrathecal chemotherapy with standard dose cytarabine will be administered at the start of each cycle, with central nervous system (CNS) therapy afterwards determined by findings on staging lumbar puncture.

Drug: Metformin; Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner.; Drug: Vincristine; 1.5 mg/m^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23; Other Names: VCR; LCR; NSC #67574; Oncovin®; Drug: Dexamethasone; 10 mg/m^2/day divided BID; Take dexamethasone by mouth days 2-15; Other Names: Decadron®; Hexadrol®; Dexone®; Dexameth®; NSC #34521 (112004); Drug: PEG-asparaginase; 2500 IU's/m^2/day; Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23; If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis.; Patients will receive Erwinase® 25,000 IU/m^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol.; Other Names: Oncaspar; Pegaspargase; Oncaspar®; NSC #644954; Polyethylene; Glycol Conjugated L-asparaginase-H; Drug: Doxorubicin; 60 mg/m^2/day IV over 15 minutes on day 2; Other Names: Adriamycin®; NSC #123127 (102004); Drug: Intrathecal chemotherapy; IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration.; 30 mg for patients age 1-1.99; 50 mg for patients age 2-2.99; 70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age.; Other Names: Ara-C; Cytosine Arabinoside; Cytosar®; NSC #63878 (102004)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Tolerated Dose (MTD)	MTD determined by Dose Limiting Toxicity (DLT), any time during the first course of therapy. Dose Limiting Toxicities: Any Grade 3 or 4 non-hematological toxicity by Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0 felt to be probably or definitely related to the study agent, persistent marrow aplasia at day 44, lactic acidosis for grade 3 or 4, grade 3 and 4 hypoglycemia.	45 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Number of Participants with Complete Remission	Patients who have: No evidence of circulating blasts or extramedullary disease;; A bone marrow with <5% blasts (M1 marrow); and; Recovery of peripheral counts (platelets ≥75,000 and absolute neutrophil count (ANC) ≥750)Qualifying marrow and peripheral counts should be performed within 1 week of each other	45 days
The Number of Participants with Biological Response to Treatment	To evaluate the biological response of ALL blasts from children receiving metformin in a window fashion and in later time points.	45 days
The Number of Participants with Adverse Events as a Measure of Safety and Feasibility	To demonstrate the safety and feasibility of the addition of metformin to induction chemotherapy for recurrent ALL.	45 Days

Collaborators and Investigators

• Sponsor: H. Lee Moffitt Cancer Center and Research Institute
• Collaborators: Pediatric Cancer Foundation
• Investigators: Principal Investigator: Damon Reed, M.D., H. Lee Moffitt Cancer Center and Research Institute; Study Chair: Julio M. Barredo, M.D., Holtz Children's Hospital University of Miami Miller School of Medicine

Publications and helpful links

Helpful Links

• Moffitt Cancer Center Clinical Trials website

Study record dates

Study Major Dates

• Study Start (Actual): July 18, 2011
• Primary Completion (Actual): November 16, 2016
• Study Completion (Actual): July 27, 2017

Study Registration Dates

• First Submitted: March 24, 2011
• First Submitted That Met QC Criteria: March 25, 2011
• First Posted (Estimate): March 28, 2011

Study Record Updates

• Last Update Posted (Actual): August 7, 2017
• Last Update Submitted That Met QC Criteria: August 4, 2017
• Last Verified: August 1, 2017

More Information

Terms related to this study

• Keywords: Relapsed; Refractory; ALL
• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid; Hypoglycemic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Enzyme Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antiemetics; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antibiotics, Antineoplastic; Dexamethasone; Metformin; Doxorubicin; Vincristine; Asparaginase; Pegaspargase
• Other Study ID Numbers: MCC-16601; Sunshine Project 001 (Other Grant/Funding Number: Pediatric Cancer Foundation)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No